Key terms
About DAWN
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DAWN news
May 10
11:15am ET
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
May 07
8:14am ET
Buy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market Entry
May 07
7:39am ET
Buy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic Commercialization
May 06
4:45pm ET
Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
May 06
4:43pm ET
Day One Biopharmaceuticals Unveils Updated Corporate Presentation
May 03
7:07am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
May 01
2:20pm ET
FDA Approval Gives Day One Biopharmaceuticals (NASDAQ:DAWN) More Room to Run
Apr 29
10:46am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Apr 26
8:05am ET
Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)
Apr 25
9:40am ET
Day One comments from call weighing on sentiment, says BofA
Apr 25
7:34am ET
Xoma earns $9M milestone as FDA grants approval of Day One’s NDA for OJEMDA
Apr 24
8:13am ET
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
Apr 24
8:07am ET
Day One Biopharmaceuticals price target raised to $33 from $30 at Needham
Apr 24
7:50am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
Apr 24
6:21am ET
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
Apr 24
5:42am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Apr 23
6:05pm ET
Buy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemda
Apr 23
4:38pm ET
Day One should rally to $17.50-$18 on approval, says JonesResearch
Apr 23
3:58pm ET
Day One confirms FDA accelerated approval of Ojemda
Apr 23
3:24pm ET
JPMorgan sees Day One moving to ‘high-teens to low-$20s’ after approval
Apr 23
3:05pm ET
Buy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospects
Apr 23
2:31pm ET
Day One up 11% to $17 after FDA grants accelerated approval
Apr 23
2:30pm ET
FDA announces accelerated approval to Day One’s tovorafenib
Apr 22
6:10am ET
Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan
Apr 22
5:46am ET
Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impact
Apr 16
9:00am ET
Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)
Apr 09
4:05pm ET
Buy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruption
Mar 26
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)
Mar 06
9:38am ET
Day One Biopharmaceuticals trading resumes
Mar 06
9:33am ET
Day One Biopharmaceuticals trading halted, volatility trading pause
Feb 29
8:31am ET
Day One Biopharmaceuticals price target lowered to $33 from $35 at Wedbush
No recent press releases are available for DAWN
DAWN Financials
Key terms
Ad Feedback
DAWN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DAWN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
